We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04586673
Recruitment Status : Completed
First Posted : October 14, 2020
Last Update Posted : August 11, 2022
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.

In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.tHIVconsv1, MV.tHIVconsv3 and MVA.tHIVconsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.

3 healthy, HIV-1 negative adult volunteers will receive one vaccination of low dose ChAdOx1.tHIVconsv1. A further 10 healthy, HIV-1 negative adult volunteers will receive a higher dose of ChAdOx1.tHIVconsv1, followed by one vaccination each of MVA.tHIVconsv3 and MVA.tHIVconsv4 4 weeks later.

Condition or disease Intervention/treatment Phase
HIV Biological: ChAdOx1.tHIVconsv1 (C1) Biological: MVA.tHIVconsv3 (M3) Biological: MVA.tHIVconsv4 (M4) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The first three participants will receive a low dose of ChAdOx1.tHIVconsv1 only. A further ten participants will receive a higher dose of ChAdOx1.tHIVconsv1 and a subsequent vaccination of MVA.tHIVconsv3 and MVA.tHIVconsv4
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase I Dose Escalation Open Label Trial to Assess Safety and Immunogenicity of Candidate ChAdOx1- and MVA- Vectored Conserved Mosaic HIV-1 Vaccines Given Sequentially to Healthy HIV-1 Negative Adult Volunteers in Oxford, UK
Actual Study Start Date : July 3, 2021
Actual Primary Completion Date : August 3, 2022
Actual Study Completion Date : August 3, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS Vaccines

Arm Intervention/treatment
Experimental: ChAdOx1.tHIVconsv1 low dose
3 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^9 vp
Biological: ChAdOx1.tHIVconsv1 (C1)
ChAdOx1.tHIVconsv1 5 x 10^9 vp

Experimental: ChADOx1.tHIVconsv1 higher dose
10 participants will receive one dose of ChAdOx1.tHIVconsv1 at 5 x 10^10 vp and one dose each of MVA.tHIVconsv3 at 1 x 10^8 pfu and MVA.tHIVconsv4 at 0.9 x 10^8 pfu.
Biological: ChAdOx1.tHIVconsv1 (C1)
ChAdOx1.tHIVconsv1 5 x 10^10 vp

Biological: MVA.tHIVconsv3 (M3)
MVA.tHIVconsv3 1 x 10^8 pfu

Biological: MVA.tHIVconsv4 (M4)
MVA.tHIVconsv4 09. x 10^8 pfu

Primary Outcome Measures :
  1. Collection of data on adverse events [ Time Frame: Up to 5 months ]
    Occurrence of reactogenicity signs and symptoms for 7 days following vaccination. Occurrence of serious adverse events during the whole study duration

Secondary Outcome Measures :
  1. Assessment of the immunogenicity of the ChAdOx1.tHIVconsv1 and MVA.tHIVconsv3 & 4 vaccines administered sequentially. [ Time Frame: Up to 5 months ]
    The proportion of participants that develop T-cell responses to tHIVconsvx measured by IFN-gamma ELISpot assay

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy adult aged 18-65 years
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Willing to allow the investigators to discuss the volunteer's medical history with their GP
  • Women of child-bearing potential agree to practice continuous effective contraception during the study and test negative for pregnancy on the day(s) of screening and vaccination
  • For sexually active men, willingness to use barrier methods for the purposes of contraception from screening until 4 months after the last vaccination
  • Agreement to refrain from blood donation during the course of the study
  • In the opinion of the Investigators, the volunteer has understood the information provided Written informed consent must be given before any study-related procedures are performed
  • Willing to undergo HCV, HBV, syphilis and HIV testing and counselling and receive test results

Exclusion Criteria:

  • Confirmed HIV-1 or HIV-2 infection
  • Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
  • Prior receipt of a recombinant simian adenoviral vaccine prior to enrolment
  • Planned receipt of another adenoviral vectored vaccine within 90 days after the vaccination with the ChAdOx1.tHIVconsv1 IMP
  • Receipt of any investigational HIV-1/2 vaccine
  • Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with the IMP
  • Receipt of other vaccine, including influenza vaccine, within the previous 14 days or planned receipt within 14 days after vaccination with the IMP
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  • Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV-1/2 infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  • Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
  • Any history of anaphylaxis in relation to vaccination
  • Pregnancy, lactation or willingness/intention to become pregnant during the study
  • History of cancer (except basal cell carcinoma of the skin)
  • History of serious psychiatric condition likely to affect participation in the study
  • Bleeding disorder (eg. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
  • Any other serious chronic illness requiring hospital specialist supervision
  • Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
  • Suspected or known injecting drug abuse in the 5 years preceding enrolment
  • Reported high-risk behaviour for HIV-1/2 infection. High-risk behaviour for HIV-1/2 infection is defined as follows. Within the previous 12 months the volunteer has:

    • Had unprotected vaginal or anal sex with a person infected with HIV and not taking effective treatment, injecting drug users or casual partners (i.e., no continuing, established relationship)
    • Engaged in sex work for money or drugs
    • Used injection drugs
    • Acquired one of the following sexually transmitted infection: chlamydia, gonorrhea and syphilis.
  • Seropositive for hepatitis B surface antigen (HBsAg)
  • Seropositive for hepatitis C virus (antibodies to HCV)
  • Untreated Syphilis: Treponemal IgG/IgM and positive RPR/TPPA AND no documentation of adequate treatment
  • Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04586673

Layout table for location information
United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
Oxford, United Kingdom, OX3 7LE
Sponsors and Collaborators
University of Oxford
Layout table for investigator information
Principal Investigator: Paola Cicconi Dr Paola Cicconi
Layout table for additonal information
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT04586673    
Other Study ID Numbers: HIV-CORE 0052
First Posted: October 14, 2020    Key Record Dates
Last Update Posted: August 11, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No